Bluejay Diagnostics Inc. Common Stock (BJDX)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, honest accounting, and a margin of safety. Bluejay Diagnostics is a six-employee medical diagnostics company with a Symphony platform of analyzers and single-use cartridges. The filed figures show no revenue in fiscal year 2023 (ended 2023-12-31), fiscal year 2024 (ended 2024-12-31), fiscal year 2025 (ended 2025-12-31), fiscal Q1 2026 (quarter ended 2026-03-31), or fiscal Q2 2026 (quarter ended 2026-06-30). A business without revenue has no proven moat; it has a product concept and a cash requirement. Net income was -$10.0M in fiscal year 2023, -$7.7M in fiscal year 2024, and -$6.8M in fiscal year 2025. In fiscal Q1 2026 and fiscal Q2 2026, net losses were -$1.9M and -$2.3M. Trailing free cash flow is -$6.2M, or -167.8% of the $3.7M market cap, a FairStock calculation. That burn is severe relative to size. The balance sheet shows low debt, with D/E 0.01, but Altman Z is -3.70, Piotroski is 3/9, ROE is -98.89%, and ROCE is -51.08%, all FairStock calculations. At the 2026-10-13 close of $0.83, P/B is 0.18 and P/E is -0.37. The P/B might look cheap, but book value can evaporate with continuing losses. The 52-week range of $0.75-$13.64 shows how far expectations have fallen. Growth cannot be evaluated because no revenue is reported. Until commercial revenue appears, this is speculation, not a Graham bargain.

In plain English: Bluejay Diagnostics is a small medical testing company that makes a device and cartridges for measuring biomarkers in blood. The business looks weak: the filed figures show no revenue and losses in each recent year, with millions of dollars of cash going out. The share price is very low compared with the company's accounting value, but that cheap look is not supported by any profits yet.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer